MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
WEB4 days ago · SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal 9/27/24 What is the news? Pfizer announced the withdrawal of voxelotor (Oxbryta®) from national and global markets on September 25, 2024. Clinical research was also stopped. “Pfizer’s decision is based on the totality of clinical data that now indicate the overall benefit of […]
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB6 days ago · NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...
FDA is alerting patients and health care professionals about the ...
WEB5 days ago · Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded ...
Healthy Returns: Pfizer pulls sickle cell disease drug from markets
WEB15 hours ago · Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.
Pfizer decision to withdrawal sickle cell drug leaves patients
WEB6 days ago · Sept. 26, 2024. Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and ...
Pfizer withdraws sickle-cell disease treatment | Reuters
WEB6 days ago · Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. ... Reuters, the news and media division of Thomson Reuters, is the world ...
Pfizer to pull sickle cell drug from market, shut down trials
WEB6 days ago · Dive Brief: Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the medicine around the world due to safety concerns. Clinical data “now indicates that the overall benefit of Oxbryta no longer outweighs the risk,” Pfizer said Wednesday. The company said data show an imbalance of deaths and ...
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB6 days ago · Sept. 25, 2024. Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including ...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB5 days ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEBPfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
- Some results have been removed